HSP-CAR30含高比例低分化T细胞可促进难治性CD30阳性淋巴瘤的持久缓解
研究开发了靶向CD30近端表位的学术型CAR-T产品HSP-CAR30,通过调节体外T细胞激活并在IL-7、IL-15基础上加入IL-21以促进T细胞干性。在10例复发/难治性经典型霍奇金淋巴瘤或CD30阳性T细胞非霍奇金淋巴瘤患者的1期试验中,未观察到剂量限制性毒性,总缓解率100%,8例霍奇金淋巴瘤中5例完全缓解,另有1例在第二次输注后完全缓解,平均随访34个月时60%患者持续完全缓解。
要点
- HSP-CAR30主要成分为记忆干细胞样和中央记忆CAR30+ T细胞(87.5%±5%)。
- 6例发生1级细胞因子释放综合征,无神经毒性,未检测到剂量限制性毒性。
- 总缓解率100%,8例霍奇金淋巴瘤中5例完全缓解,平均随访34个月时60%持续完全缓解。
核心结论
- 选择靶向CD30的表位及体外保留低分化记忆T细胞可能增强CART30在难治性霍奇金淋巴瘤患者中的疗效。
研究设计与样本
- 学术型CART30产品HSP-CAR30的1期临床试验,纳入10例复发/难治性经典型霍奇金淋巴瘤或CD30阳性T细胞非霍奇金淋巴瘤患者,试验注册号NCT04653649。
主要发现
- HSP-CAR30主要成分为记忆干细胞样和中央记忆CAR30+ T细胞(87.5%±5%)。
- 未检测到剂量限制性毒性;6例发生1级细胞因子释放综合征,无患者出现神经毒性。
- 总缓解率100%,8例霍奇金淋巴瘤中5例达到完全缓解。
- 另有1例霍奇金淋巴瘤患者在第二次HSP-CAR30输注后达到完全缓解。
- 平均随访34个月时,60%患者持续完全缓解。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CD30-directed chimeric antigen receptor T-cell therapy (CART30) has limited efficacy in relapsed or refractory patients with CD30+ lymphoma, with a low proportion of durable responses. We have developed an academic CART30 cell product (HSP-CAR30) by combining strategies to improve performance. HSP-CAR30 targets a proximal epitope within the nonsoluble part of CD30, and the manufacturing process includes a modulation of ex vivo T-cell activation, as well as the addition of interleukin-21 (IL-21) to IL-7 and IL-15 to promote stemness of T cells. We translated HSP-CAR30 to a phase 1 clinical trial of 10 patients with relapsed/refractory classic Hodgkin lymphoma (HL) or CD30+ T-cell non-Hodgkin lymphoma. HSP-CAR30 was mainly composed of memory stem-like (TSCM-like) and central memory (TCM) CAR30+ T cells (87.5% ± 5%). No dose-limiting toxicities were detected. Six patients had grade 1 cytokine release syndrome, and no patient developed neurotoxicity. The overall response rate was 100%, and 5 of 8 patients with HL achieved complete remission (CR). An additional patient with HL achieved CR after a second HSP-CAR30 infusion. Remarkably, 60% of patients have ongoing CR after a mean follow-up of 34 months. CAR30+ T cells at expansion peak had a predominance of TSCM and TCM cells, and CAR30+ T cells remained detectable in 3 of 5 evaluable patients at least 12 months after infusion. Our study shows that selection of the epitope targeting CD30 and ex vivo preservation of less-differentiated memory T cells may enhance the efficacy of CART30 in patients with refractory HL. This trial is registered at www.clinicaltrials.gov (NCT04653649).
引用
- Caballero AC, Ujaldón-Miró C, Pujol-Fernández P, et al. HSP-CAR30 with a high proportion of less-differentiated T cells promotes durable responses in refractory CD30+ lymphoma. Blood. 2025. PMID: 39841453. doi:10.1182/blood.2024026758
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。